Regenobody S.A. Obtains License From the Dominican Republic to Harvest, Incubate, and Transplant Stem Cells
SOSUA BAY, Dominican Republic, Jan 12, 2010 (GlobeNewswire via COMTEX) -- Proton Laboratories, Inc. (Pink Sheets:PLBI), through the newly acquired Regenobody S.A, has obtained a license, through LifeXtension Worldwide, from the Government of the Dominican Republic for harvesting, incubating, and transplanting stems cells.
Armando Casciati, President of Proton Laboratories, Inc., stated; "This is tremendous news for our company. Very rarely are companies licensed by their respective governments to conduct research, harvest, and incubate stems cells while then being able to transplant these cells back to the patients for therapeutic benefit." Regenobody S.A. will be utilizing procedures and equipment obtained through an EXCLUSIVE Caribbean license from its Korean licensor and patent holder, RNL BIO Co. Ltd. Prior to Regenobody S.A. obtaining the EXCLUSIVE Caribbean licensing rights, these procedures were only available in Japan, Korea, and China. More information may be seen at the Company's website www.regenobody.com. Mr. Casciati went on to state that; "We are focused on developing a world class facility with world class equipment, technicians and procedures to allow patients the ability to utilize their own stem cells, mainly obtained through the fatty tissues of the stomach, to improve their lives."
The statements made in this release contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial conditions and other aspects of the company to which this release pertains. The actual results of specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although the statements are based upon the best judgments of management of the company as of the date of this release, significant deviation in magnitude, timing and other factors may result from business risks and uncertainties including without limitation, the company's dependence on third parties, market conditions, technical factors, the availability of outside capital and receipt of revenues, and other factors, many of which are beyond the control of the Company.
SOSUA BAY, Dominican Republic, Jan 12, 2010 (GlobeNewswire via COMTEX) -- Proton Laboratories, Inc. (Pink Sheets:PLBI), through the newly acquired Regenobody S.A, has obtained a license, through LifeXtension Worldwide, from the Government of the Dominican Republic for harvesting, incubating, and transplanting stems cells.
Armando Casciati, President of Proton Laboratories, Inc., stated; "This is tremendous news for our company. Very rarely are companies licensed by their respective governments to conduct research, harvest, and incubate stems cells while then being able to transplant these cells back to the patients for therapeutic benefit." Regenobody S.A. will be utilizing procedures and equipment obtained through an EXCLUSIVE Caribbean license from its Korean licensor and patent holder, RNL BIO Co. Ltd. Prior to Regenobody S.A. obtaining the EXCLUSIVE Caribbean licensing rights, these procedures were only available in Japan, Korea, and China. More information may be seen at the Company's website www.regenobody.com. Mr. Casciati went on to state that; "We are focused on developing a world class facility with world class equipment, technicians and procedures to allow patients the ability to utilize their own stem cells, mainly obtained through the fatty tissues of the stomach, to improve their lives."
The statements made in this release contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial conditions and other aspects of the company to which this release pertains. The actual results of specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although the statements are based upon the best judgments of management of the company as of the date of this release, significant deviation in magnitude, timing and other factors may result from business risks and uncertainties including without limitation, the company's dependence on third parties, market conditions, technical factors, the availability of outside capital and receipt of revenues, and other factors, many of which are beyond the control of the Company.
